Overview
Patient Perception Study for AL-4943A
Status:
Completed
Completed
Trial end date:
2011-10-01
2011-10-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
To evaluate patient perceptions of Al-4943 in subjects with allergic conjunctivitis previously treated with a topical ocular anti-allergy leukotriene-release inhibitor medication.Phase:
Phase 4Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Alcon ResearchTreatments:
Olopatadine Hydrochloride
Criteria
Inclusion Criteria:- History of allergic conjunctivitis within last 24 months
- Active signs and symptoms of ocular allergies
Exclusion Criteria:
- Severe or serious ocular condition, ocular surgical intervention, ocular infection